Top Markets
#1 Akedo Akedo +73.50%
#2 MEET48 MEET48 +26.11%
#3 Bitway Bitway +21.76%
#4 VeThor VeThor +21.08%
#5 Power Protocol Power Protocol +17.38%
#6 Tutorial Tutorial +16.23%
#7 Astar Astar +14.86%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.72%
#9 Falcon Finance Falcon Finance +12.11%
#10 Arbitrum Arbitrum +12.09%
Coin of the day
Akedo Akedo
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Kedudukan dalam Saham #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Harga Saham
$0.25974701
Disegerakkan terakhir: 2025-01-06
Modal Pasaran
$2.04M
Perubahan (1 hari)
0.74%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Acticor Biotech SAS (ALACT)

Kategori

Healthcare
Hasil untuk Acticor Biotech SAS (ALACT)
Hasil pada Jun 2024 TTM: 0.00
Menurut laporan kewangan terkini daripada Acticor Biotech SAS, hasil semasa syarikat (TTM) ialah 0.00. Pada tahun 2022, syarikat memperoleh hasil sebanyak 0.00 sama dengan hasil pada tahun 2021 iaitu 0.00. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Acticor Biotech SAS dari 2010 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 $57.46K -99.46%
2017 $10.59M -27.26%
2016 $14.56M -21.24%
2015 $18.49M -22.69%
2014 $23.92M -0.83%
2013 $24.11M 21.74%
2012 $19.81M 44.80%
2011 $13.68M 52.66%
2010 $8.96M 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH